ERBB2 and gastroesophageal junction adenocarcinoma: Furthermore, in 2020, the FDA granted this ADC breakthrough therapy designation for treatment of patients with metastatic, HER2-mutated non-small cell lung cancer (NSCLC) after a platinum-based therapy, and priority review for treatment of HER2+ metastatic gastric or gastroesophageal junction adenocarcinoma.